真实世界早期腹主动脉瘤修复的后果:成本效益分析
基于血管质量倡议和PHAST数据,真实世界EVAR干预直径中位数约54 mm,低于共识阈值55 mm。多状态模型估计,提前约2年修复可降低小动脉瘤患者总死亡率2.3%,但增加EVAR手术量及费用。
要点
- 真实世界EVAR干预直径较共识阈值提前约5 mm,相当于提前约2年修复。
- 早期修复降低小动脉瘤患者总死亡率2.3%,但增加21.9%的EVAR手术量。
研究设计与样本
- 基于血管质量倡议和PHAST报告数据的差异分析,并采用基于EVAR Medicare人群生命表的多状态模型进行估计。
主要发现
- 真实世界与共识阈值的AAA直径差异约5 mm,按年增长2.5 mm计算相当于提前约2年修复。
- 早期修复使小动脉瘤患者总体死亡率降低2.3%,EVAR手术量增加21.9%。
- 早期修复增加EVAR相关死亡,开放再干预增加42.3%,血管内再干预增加36.8%。
- 在超过30000例AAA患者中,估计减少482例AAA相关死亡,但增加140例EVAR相关死亡。
- Medicare人群8年观察期内健康成本增加3亿美元。
关键数值与推荐
- 真实世界EVAR干预直径中位数54 mm(血管质量倡议和PHAST数据),共识干预阈值为55 mm。
- 假设AAA年增长率为2.5 mm。
- 早期修复降低小动脉瘤患者总体死亡率2.3%。
- EVAR手术量增加21.9%,开放再干预增加42.3%,血管内再干预增加36.8%。
临床怎么用
- 临床决策需权衡早期EVAR降低破裂死亡与增加手术相关死亡及再干预、成本的关系。
- 对小于共识阈值的小动脉瘤,应严格评估早期干预的获益与资源消耗。
局限性
- 结论基于报告数据和模型估计,非直接临床 trial 证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reported 54 mm median intervention diameter for endovascular aneurysm repair (EVAR) in the Vascular Quality Initiative and European data from the Pharmaceutical Aneurysm Stabilisation Trial (PHAST) implies that in real life the majority of abdominal aortic aneurysm (AAA) repairs occur at diameters smaller than the consensus intervention threshold of 55 mm. This study explores the potential consequences of this practice. METHODS: The differences between real life AAA repair and consensus based intervention threshold were explored in reported data from vascular quality initiatives and PHAST. The subsequent consequences of advancement of endovascular aneurysm repair (EVAR) were estimated using a multistate model based on life tables for the EVAR Medicare population. RESULTS: There appears an approximate 5 mm difference in AAA diameter between real life practice and consensus intervention threshold. Assuming a 2.5 mm annual growth rate, this results in an approximately 2 year advancement of AAA repair. According to the model used, early repair reduces overall small aneurysm patient mortality by 2.3%, it results in 21.9% more EVAR procedures, more EVAR related deaths, and 42.3% and 36.8% more open and endovascular re-interventions, respectively. Cost-benefit estimates imply 482 fewer AAA related deaths, but 140 extra EVAR related deaths for a population of more than 30,000 AAA patients, and a 300 million USD increase in health costs for the 8 year observation period in the Medicare population. CONCLUSIONS: In the real life situation a large proportion of EVAR procedures appear to occur before reaching the consensus threshold. Although this reduces mortality, it comes at a cost of approximately 1 million USD per prevented rupture related death.
引用
- Tomee SM, Bastiaannet E, Schermerhorn ML, et al. The Consequences of Real Life Practice of Early Abdominal Aortic Aneurysm Repair: A Cost-Benefit Analysis. Eur J Vasc Endovasc Surg. 2017. PMID: 28506561. doi:10.1016/j.ejvs.2017.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。